COST-EFFECTIVENESS STUDY STANDARDS SHOULD ACCEPT GREATER UNCERTAINTY, MEDTAP's LUCE TELLS CEPOR; NATURALISTIC TRIALS COULD BE EFFECTIVENESS GOLD STANDARD
Executive Summary
FDA and industry should consider accepting more uncertainty in cost-effectiveness analysis of pharmaceuticals, MEDTAP International CEO Bryan Luce recommended at the University of North Carolina- Chapel Hill's Center for Pharmaceutical Outcomes Research conference March 31-April 2.